Tested Applications
| Positive WB detected in | PMA, Ionomycin and Brefeldin A treated CTLL-2 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
29788-1-AP targets IFN-gamma in WB, IHC, IF, ELISA applications and shows reactivity with mouse samples.
| Tested Reactivity | mouse |
| Cited Reactivity | mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Recombinant protein Predict reactive species |
| Full Name | interferon gamma |
| Calculated Molecular Weight | 17 kDa |
| Observed Molecular Weight | 15-18 kDa |
| GenBank Accession Number | BC119063 |
| Gene Symbol | IFN gamma |
| Gene ID (NCBI) | 15978 |
| RRID | AB_3086161 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P01580 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
IFN gamma (IFNG) is a soluble cytokine that is the only member of the type II class of IFN. It is secreted by Th1 cells, cytotoxic T cells and NK cells. The cytokine is associated with antiviral, immunoregulatory and anti-tumor properties and is a potent activator of macrophages. It plays crucial roles in pathogen clearance. Aberrant IFNG expression is associated with a number of autoinflammatory and autoimmune diseases. It has been identified in many studies as a biomarker for pleural tuberculosis (TB).
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for IFN-gamma antibody 29788-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The IFN-gamma Polyclonal antibody (Cat# 29788-1-AP) has 18 citations published in journals including Nature Communications, Molecular Cancer, Cell Reports Medicine, Biomaterials, Pharmacological Research, NPJ Precision Oncology, Cancer Cell International, Frontiers in Immunology, Journal of Ethnopharmacology, Pharmaceuticals, Inflammation, Bioorganic Chemistry, Cell Signaling, American Journal of Cancer Research, Viruses, Biochemical Pharmacology, and Nan Fang Yi Ke Da Xue Xue Bao. Research fields span cancer immunotherapy, inflammation, infectious disease, gut microbiome, ferroptosis, and angiogenesis.
| Species | Application | Title |
|---|---|---|
Mol Cancer Tumour-infiltrating microplastics disrupt the JAK-STAT-microbiota axis to promote immunotherapy resistance in colorectal cancer. | ||
Nat Commun YBX1 Confers immunosuppressive bone metastatic traits in non-small cell lung cancer. | ||
Cell Rep Med HE4 drives PD-L1 expression in myeloid cells via IFN-γR-JAK-STAT3 signaling to promote tumor immune evasion. | ||
Biomaterials Innovative DNA tetrahedron inspired by ancient mortise-and-tenon technique offers new immunotherapy strategy for metastatic breast cancer | ||
Biomaterials Bioinspired enzyme-catalytic nanoreactor enhances immunotherapy for spinal metastases by activating pyroptosis and the cGAS-STING pathway. | ||
Pharmacol Res Systematic druggable genome-wide Mendelian randomization to identify therapeutic targets and dominant flora for ulcerative colitis |
